Enjoy complimentary customisation on priority with our Enterprise License!
The Antibody Drug Conjugates (ADC) Market size is estimated to grow by USD 9.95 billion at a CAGR of 15.06% between 2023 and 2028. The growing prevalence of cancer and other diseases has spurred technological advancements in the development of Antibody-Drug Conjugates (ADCs). With increasing investments in pharmaceutical research and development, there's a focused effort to harness these advancements for more effective treatments. ADCs, which combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, hold promise for targeted therapy with reduced side effects. This approach represents a significant breakthrough in oncology and beyond, offering new avenues for personalized medicine. As the landscape of healthcare evolves, the emphasis on innovative therapies like ADCs underscores the industry's commitment to combating diseases and improving patient outcomes through cutting-edge treatments.
To learn more about this report, Request Free Sample
The breast cancer segment is estimated to witness significant growth during the forecast period. This segment is one that is both significant and expanding quickly within the global antibody drug conjugates (ADC) market. ADCs refer to a class of targeted cancer therapy that combines the cytotoxic qualities of chemotherapeutic medicines with the specificity of monoclonal antibodies.
Get a glance at the market contribution of various segments Download PDF Sample
The breast cancer segment was the largest segment and was valued at USD 3.22 billion in 2018. Moreover, breast cancer is one of the most prevalent cancers worldwide, especially in women. In addition, it is linked to a high rate of morbidity and is responsible for a sizable portion of cancer-related fatalities. Therefore, it is crucial to establish efficient and focused breast cancer therapy choices. Furthermore, ADCs provide a viable alternative for treating breast cancer as they target cancer cells specifically and deliver cytotoxic medicines straight to the tumor site. In addition, this targeted delivery reduces the potential side effects associated with traditional chemotherapy, such as damage to healthy cells and tissues. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
The cleavable linker segment is a major component of the global antibody drug conjugates market. In addition, ADCs are a brand-new family of targeted therapeutic agents that combine small-molecule medicinal potency with the specificity of monoclonal antibodies (MAbs). Moreover, the ability to selectively release the drug inside the intended cancer cell is made possible by the cleavable linker, which connects the cytotoxic payload (drug) and the antibody. In addition, the cleavable linker is intended to cleave effectively and selectively in the target cell to enable successful drug delivery, but it should also be stable in circulation to prevent premature drug release. .Furthermore, advanced cleavable linkers are witnessing increasing demand as ADC development moves forward. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 50% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The antibody drug conjugates (ADCs) market is expanding quickly in North America due to the factors such as the presence of a significant number of pharmaceutical companies, a well-established healthcare infrastructure, and advantageous reimbursement policies. In addition, ADCs are a family of targeted cancer medicines that combine cytotoxic drugs that kill cancer cells with monoclonal antibodies, which target particular cancer cells. Moreover, due to its modern healthcare facilities and the high prevalence of cancer, the US accounts for the biggest market share in North America. The region's rising cancer incidence rate, increased investments in the biopharmaceutical industry, and an increase in research and development efforts are driving the market growth in North America during the forecast period.
The Antibody Drug Conjugates (ADCs) Market, driven by Conjugation techniques like Protein-drug conjugation and Polymer-drug conjugation, offers promising Prodrugs combining cytotoxic Drugs with Monoclonal Antibodies. Polymers, Lipids, and Polypeptides play critical roles in ADC development. T-cell dual affinity re-targeting conjugation enhances specificity. Pharmacokinetics of ADCs, including Payload and Linker stability, impact efficacy. Biopharmaceutical drugs like Chemotherapy, Antibodies, and Immune system modulators target Surface Antigens on Tumour cells. Angiogenesis inhibitors and Multi-specific Antibodies Therapy further refine treatment. Despite challenges such as high development costs, ADCs continue to revolutionize Immunotherapy, driving market growth.
The market is driven by the rapid expansion of Antibody-Drug Conjugates (ADCs) in North America. ADCs, a class of targeted cancer therapies, blend cytotoxic drugs with monoclonal antibodies to selectively attack tumor cells. North America holds a dominant position globally due to numerous pharmaceutical firms, robust healthcare infrastructure, and favorable reimbursement policies. The US leads in market share, buoyed by advanced healthcare facilities and high cancer prevalence. Anticipated growth in the coming years is propelled by rising cancer rates, increased biopharmaceutical investments, and heightened research efforts.
Major pharmaceutical players like Pfizer Inc. and F. Hoffmann La Roche Ltd. dominate the competitive landscape through strategic partnerships. Polymer-drug conjugation and T-cell dual affinity re-targeting conjugation are emerging as promising techniques in ADC development. Despite bright prospects, challenges such as development costs, stringent regulations, and potential toxicity persist. The COVID-19 pandemic initially disrupted ADC supply chains but rebounded with governmental vaccination drives, underscoring the market's resilience amidst challenges.
With cancer cases soaring, the demand for effective treatments ensures continued market growth. Notable ADCs include ado-trastuzumab emtansine (Kadcyla), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), polatuzumab vedotin-piiq (Polivy), enfortumab vedotin (Padcev), sacituzumab govitecan (Trodelvy), trastuzumab deruxtecan (Enhertu), belantamab mafodotin-blmf (Blenrep), mirvetuximab soravtansine (Elahere), tisotumab vedotin (Tivdak), cetuximab sarotalocan (Akalux), disitamab vedotin (Aidixi), and loncastuximab tesirine-lpyl (Zynlonta). Pharmacokinetics and angiogenesis inhibitors play crucial roles in enhancing ADC efficacy. The development of tumor antigen-specific antibodies and anti-HER2 medications like valine citrulline (VC) showcases ongoing advancements in the field.
A key factor shaping the antibody drug conjugates market growth is the increasing adoption and development of targeted therapies. There has been an increasing acceptance and development of targeted therapies, which is a notable trend in the global antibody drug conjugates market. In addition, ADCs, or antibody drug conjugates, are a family of biopharmaceutical medications that target cancer cells specifically with deadly chemicals by using monoclonal antibodies.
Moreover, pharmaceutical firms and medical experts are taking notice of these innovative drugs as they appear to be effective in treating a variety of cancers. In addition, growing knowledge of the underlying molecular pathways of cancer progression is one of the key drivers propelling the use of targeted therapies. Hence, such factors are positively impacting the antibody drug conjugates (ADC) market. Therefore, it is expected to drive the market growth during the forecast period.
High development costs for antibody drug conjugates are one of the key challenges hindering the antibody drug conjugates market growth. The global antibody drug conjugates market is facing high development costs, which poses a major challenge to market growth. In addition, ADCs are a class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapy drugs.
Moreover, developing and manufacturing ADCs involves multiple complex processes, making it a costly endeavor. For instance, it takes a lot of research and development to create an ADC, including choosing appropriate targets, creating the antibody, and attaching it to the cytotoxic agent. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Antibody Drug Conjugates Market Customer Landscape
The antibody drug conjugates market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
You may also be interested in below market reports:
Immunohistochemistry (IHC) market: Immunohistochemistry (IHC) market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, UK, China - Size and Forecast
Pharmaceutical Contract Manufacturing Market: Pharmaceutical Contract Manufacturing Market Analysis North America, Asia, Europe, Rest of World (ROW) - US, Germany, UK, China, India - Size and Forecast
High-performance Liquid Chromatography (HPLC) Market: High-performance Liquid Chromatography (HPLC) Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, France - Size and Forecast
The Antibody Drug Conjugates (ADCs) market is witnessing significant advancements in conjugation technology, integrating prodrugs, polypeptides, lipids, polymers, and carbohydrates with therapeutic proteins. This innovative approach, including protein-drug conjugation and antibody-drug conjugation, has revolutionized biopharmaceutical drugs, particularly in immunotherapy. By targeting surface antigens on tumor cells, ADCs deliver potent anti-cancer agents directly to the site of action, minimizing off-target effects. Notable examples include Kadcyla, Enhertu, and Adcetris, which employ chemical linkers to attach cytotoxic payloads like MMAE and DM4 to monoclonal antibodies such as trastuzumab and brentuximab vedotin (Adcetris).
Moreover, these advancements extend to multi-specific antibodies therapy, combining anti-angiogenic agents and DNA damage response agents to enhance efficacy. Moreover, ADCs like Padcev and Trodelvy demonstrate promising outcomes in targeting PD-L1 and MHC molecules, bolstering the immune system response against cancer. As market research and growth projects a robust trajectory for ADCs, including market growth and forecasting and market forecasting, ongoing developments in bioconjugation techniques and the introduction of novel agents like Polivy and Tivdak are poised to further drive the market forward.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
156 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 15.06% |
|
Market Growth 2024-2028 |
USD 9.95 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
14.35 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 50% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Adcendo ApS, Araris Biotech AG, Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., ImmunoGen Inc., Merck KGaA, Mersana Therapeutics Inc., Mythic Therapeutics, Pfizer Inc., Piramal Enterprises Ltd., PPF Group, Regeneron Pharmaceuticals Inc., Seagen Inc., Syngene International Ltd., Takeda Pharmaceutical Co. Ltd., and ADC Therapeutics SA |
|
Market dynamics |
Parent market analysis, Market forecasting growth analysis and inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Technology
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
